In motion, a clinical trial of JAK2 inhibitor in diabetic kidney diseases is ongoing with good signs for protecting efficacy.62 Although JAK/STAT pathways exert various functions in renal fibrosis,63, 64, 65, 66 we believe that GSK3β/β‐catenin signalling is an important downstream effector that should not to be ignored. The gene discussed is JAK2; the disease is diabetic kidney disease.